CCL2 and neoplasm: In mice, pharmacologically blocking CCL2/CCR2 axis through an anti-CCL2 neutralizing antibody or CCR2 inhibitor resulted in reduced CCR2+ monocytes and TAMs in primary PDAC and pre-metastatic liver, which consequently contributed to improved anti-tumor immunity, reduced tumor growth, and decreased metastasis (116, 117).